Definium Therapeutics Archives

What do Definium Therapeutics’ Panorama results mean for DT120 FDA approval?

by Pallavi Madhiraju
September 15, 2026
0 Comments

Definium’s DT120 delivers another positive Phase 3 anxiety result, putting the FDA filing and commercialization strategy firmly in focus.

Representative image: Definium Therapeutics’ $805 million public offering strengthens its ability to advance DT120 ODT after positive Phase 3 depression trial results, while regulatory and commercial execution remain the next major tests.

Pharma & Biotech

DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?

by Pallavi Madhiraju
June 26, 2026
0 Comments

Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.

A clinician monitors a supervised treatment session as Definium Therapeutics advances DT120, a single-dose investigational therapy for major depressive disorder, following positive Phase 3 results. Representative image.

Pharma & Biotech

Can Definium turn a 50% stock surge into an FDA path for single-dose depression therapy?

by Pallavi Madhiraju
June 23, 2026
0 Comments

DT120 produced a striking Phase 3 antidepressant effect after one supervised dose, but confirmation, functional unblinding, controlled-substance rules and treatment-site economics remain decisive.